Tonix signs on Rho to support NDA submission for fibromyalgia drug

2024-02-14

临床结果临床3期申请上市临床2期

Tonix signs on Rho to support NDA submission for fibromyalgia drug

Preview

来源: FierceBiotech

A phase 3 study assessing Tonix's Tonmya found that the drug reduced daily pain compared to placebo for patients with fibromyalgia.

Tonix Pharmaceuticals has tapped CRO Rho to support the New Jersey-based biotech’s plans to submit a new drug application (NDA) for its drug designed to manage fibromyalgia.

The deal follows the December release of phase 3 study results assessing Tonmya, a sublingual tablet formulation of cyclobenzaprine hydrochloride. In the study, the drug reduced daily pain compared to placebo in participants with fibromyalgia, a result that was statistically significant.

Financial terms of the new agreement weren’t disclosed.

“We intend to meet with the FDA in the first half of this year and to submit our NDA in the second half of the year,” Tonix CEO Seth Lederman, M.D., said in the release. “We believe we have completed all development work required for the NDA, including CMC requirements and the completion of two positive phase 3 studies.”

Tonix had hoped its investigations into cyclobenzaprine for fibromyalgia-like long COVID would succeed. However, the company abandoned that indication last September after it failed to show a statistically significant improvement in pain symptoms compared to placebo in a phase 2 trial of patients with long COVID.

In November, Tonix's pipeline took another hit as the biotech dropped a major depression disorder therapy due to a phase 2 flop. The biotech is now focusing resources on central nervous system R&D.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构